Search results
Results from the WOW.Com Content Network
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Will that trend continue in ...
When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back some of those gains, but still finished the year, as mentioned above ...
In the third quarter, the company's revenue of $2.77 billion increased by 12% year over year, a strong performance for a biotech giant. The company's best CF treatment yet, Trikafta, accounted for ...
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an impressive resume already, but it's just getting started. It's currently in the ...
Over time, you can benefit from these periods by buying shares of certain biotech and pharma companies and holding for the long term. Prediction: These Could Be the Best-Performing Pharma and ...
CRISPR's shares are down by 27% year to date, and Moderna's are down by 41%. Regardless of their performances so far in 2024, both stocks are worth investing in this month. Read on to find out why. 1.
The Ultimate Biotech Stock to Buy With $50 Right Now. ... 2024 at 6:32 AM. ... An Arkansas organist is playing 18 hours of Bach this year, 1 lunch break at a time. News. News. Reuters
In the second quarter, revenue increased by 6% year over year to $2.65 billion. And Vertex's top line will start growing faster soon; the company is awaiting approval of a newer, better CF therapy.